Spero Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
SP001 is being advanced into a two-dose IgG4-RD phase II trial planned for Q2 2027, targeting disease biology beyond flares. $105 million in non-dilutive financing supports a runway into H2 2029.
-
SP001’s upstream CD40 ligand mechanism is being advanced for IgG4-related disease, with prior Sjögren’s data supporting continued development. A phase II trial is planned to start in Q2 2027.
-
FDA approved Utebzi, enabling a strategic pivot to immunology with the in-licensing of SP001 and $105M non-dilutive financing. Cash runway now extends into H2 2029, with a phase II trial for SP001 in IgG4-RD planned for 2027.
-
The meeting covered director elections, auditor ratification, executive compensation, an increase in authorized shares, and a new stock incentive plan. All proposals passed with a quorum present, and voting results will be published in a Form 8-K.
Fiscal Year 2025
-
Phase III trial for tebipenem HBr in cUTI met its primary endpoint and was stopped early for efficacy, with regulatory submission planned by year-end 2025. Revenue rose 39% year-over-year, net loss narrowed, and cash runway now extends into 2028.
-
A diversified infectious disease pipeline is advancing, with the lead oral carbapenem asset nearing phase III enrollment completion for cUTI. Key partnerships and a strong financial position support ongoing development, with major data and regulatory milestones expected in the second half of the year.
Fiscal Year 2024
-
Tebipenem HBr phase III trial continues, with interim analysis expected in Q2 2025 and GSK set to assume regulatory and commercialization roles if successful. Revenue and net income declined year-over-year due to lower collaboration revenue and higher R&D expenses. Cash runway extends into Q2 2026.
-
Focused on rare and infectious diseases, the company is advancing SPR720, tebipenem, and SPR206, with key data readouts and regulatory milestones expected over the next year. Strong partnerships and a solid cash position support ongoing development and potential pipeline growth.
-
A diversified portfolio targets rare and resistant infections, with SPR720 poised for a key data readout in Q4 2024 as a potential first oral therapy for NTM-PD. Tebipenem HBr, partnered with GSK, advances in phase III for urinary tract infections, offering significant commercial and clinical impact.
-
Q2 2024 saw increased revenue and R&D expenses, with a net loss of $17.9 million. Clinical progress continued for SPR720, Tebipenem HBr, and SPR206, with key data readouts and milestones expected in late 2024 and 2025. Cash runway extends into late 2025.